Dopamine agonists in Parkinson's disease: a look at apomorphine
The DOI matches its Crossref record.
Abstract
Summary— Apomorphine is a D1 and D2 dopamine receptor agonist with anti‐parkinsonian properties qualitatively similar to those seen with l‐dopa. It was first used in the treatment of Parkinson's disease by Schwab in the 1950s but owing to its short duration of action, the need for parenteral administration, and adverse reactions including nausea, vomiting, postural hypotension and sedation, it was not widely prescribed. In the early 1970s, Cotzias confirmed its potent anti‐parkinsonian effects and that some of its secondary effects were diametrically opposite to those seen with l‐dopa. The advent of peripheral dopamine receptor antagonist drugs, which counteract the unwanted effects of apomorphine, and the development of new drug delivery systems including insulin pens and ambulatory mini pumps have led to the resurrection of apomorphine for the treatment of Parkinson's disease. Over the last five years in Europe, the drug has proved to be a major advance in the treatment of refractory “on‐off” oscillations in Parkinson's disease. It has also been used as a diagnostic test for dopaminergic responsiveness in Parkinson syndromes and tremors of uncertain aetiology. The drug has also proved particularly useful in dealing with certain “off‐period” disabilities, including pain, bladder dysfunction, dystonia and gastro‐intestinal symptoms. Continuous steady state infusion of apomorphine by mini‐pump may reduce the severity of “on” phase dyskinesias over time. The drug has also proved useful in the clinical pharmacological investigation of the pathophysiology of the motor response to dopaminergic drugs in Parkinsons's disease and the occurrence of involuntary movement sequences. Neuropsychiatry side‐effects are relatively infrequent when compared with ergolene dopamine agonists. Studies with apomorphine raise the hope that it may be possible to develop a long acting, orally active dopamine receptor agonist with therapeutic effect comparable to that observed with l‐dopa and with fewer long term adverse reactions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Duty, S., & Jenner, P. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01426.x · Cited by 753
Samuels, E., & Szabadi, E. (2008) · Current Neuropharmacology · doi:10.2174/157015908785777193 · Cited by 454
Deleu, D., Northway, M. G., & Hanssens, Y. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241040-00003 · Cited by 349
The Role of Iron in Neurodegeneration: Prospects for Pharmacotherapy of Parkinson??s Disease
Jellinger, K. A. (1999) · Drugs & Aging · doi:10.2165/00002512-199914020-00004 · Cited by 218
“[229-235] These include apomorphine, which has been shown to be a highly potent iron chelator, antioxidant and free radical scavenger,[236-239] and which protects mesencephalic neurons form glutamate neurotoxicity.”
BackgroundNeuroprotective effects of Bacopa monnieri in experimental model of dementia
Saini, N., Singh, D., & Sandhir, R. (2012) · Neurochemical Research · doi:10.1007/s11064-012-0811-4 · Cited by 95
“Alterations in Na K-ATPase activity may induce neuronal death with features of both apoptosis and necrosis [80].”
Metadata
- Authors
- Lees, A.
- Venue
- Fundamental & Clinical Pharmacology
- Publisher
- Wiley
- Published
- 1993-04
- Volume
- 7
- Issue
- 3-4
- Pages
- 121-128
- ISSN
- 0767-3981 (ISSN-L)
- 1472-8206
- OpenAlex
- W2079806597
- Cited by
- 135
- References
- 0
- FWCI
- 3.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dopamine agonists in Parkinson's disease: a look at apomorphine. https://app.cochat.ai/papers/10.1111/j.1472-8206.1993.tb00226.x
- The paper
- Lees, A. (1993). Dopamine agonists in Parkinson's disease: a look at apomorphine. Fundamental & Clinical Pharmacology. https://doi.org/10.1111/j.1472-8206.1993.tb00226.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.